Laboratory Corporation of America Holdings (NYSE:LH) is set to announce third quarter earning results on Tuesday 27th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, LH to report 3Q20 income of $ 5.25 per share.
For the full year, analysts anticipate top line of $ 12752.70 million, while looking forward to income of $ 14.46 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 12,012.00 million ~ $ 12,243.00 million, where as bottomline are predicted in a range of $ 11.75 ~ $ 12.15 per share
Click Here For More Historical Outlooks Of Laboratory Corporation of America Holdings
Previous Quarter Performance
Laboratory Corporation of America Holdings outlined income for the second quarter of $ 2.57 per share, from the revenue of $ 2,769.00 million. The quarterly earnings 12.29 percent while revenues fell 3.91 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.99 per share from $ 2504.89 million in revenue. The bottom line results beat street analysts by $ 1.58 or 159.60 percent, at the same time, top line results outshined analysts by $ 264.11 million or 10.54 percent.
Stock Performance
Shares of Laboratory Corporation of America Holdings traded up $ 2.23 or 1.09 percent on Friday, reaching $ 207.49 with volume of 666.60 thousand shares. Laboratory Corporation of America Holdings has traded high as $ 211.21 and has cracked $ 206.09 on the downward trend
According to the previous trading day, closing price of $ 207.49, representing a 109.41 % increase from the 52 week low of $ 98.02 and a 2.82 % decrease over the 52 week high of $ 211.21.
The company has a market capital of $ 20.21 billion and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Laboratory Corporation of America Holdings will be hosting a conference call at 9:00 AM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.labcorp.com
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
